Sanofi $SNY Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lessened its holdings in shares of Sanofi (NASDAQ:SNY) by 3.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 2,128,717 shares of the company’s stock after selling 71,390 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Sanofi were worth $103,161,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in SNY. Brighton Jones LLC raised its holdings in shares of Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after buying an additional 1,869 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of Sanofi by 107.2% during the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock valued at $1,693,000 after buying an additional 15,791 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Sanofi by 1.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock valued at $2,732,000 after buying an additional 752 shares during the last quarter. Sivia Capital Partners LLC raised its holdings in shares of Sanofi by 5.4% during the second quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock valued at $326,000 after buying an additional 347 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Sanofi by 36.1% during the second quarter. EverSource Wealth Advisors LLC now owns 3,301 shares of the company’s stock valued at $159,000 after buying an additional 875 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sanofi in a report on Friday, January 16th. Citigroup restated a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. Weiss Ratings upgraded shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday. BNP Paribas Exane downgraded shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research report on Monday, April 20th. Finally, UBS Group reissued a “neutral” rating on shares of Sanofi in a report on Friday, January 16th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $51.00.

Sanofi Price Performance

NASDAQ SNY opened at $42.85 on Friday. The stock has a market capitalization of $104.51 billion, a P/E ratio of 11.97, a P/E/G ratio of 1.04 and a beta of 0.35. Sanofi has a 1 year low of $42.33 and a 1 year high of $53.36. The business’s fifty day moving average is $45.67 and its two-hundred day moving average is $47.50. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.22 and a current ratio of 1.01.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th will be issued a $2.4225 dividend. This is an increase from Sanofi’s previous annual dividend of $2.04. This represents a dividend yield of 559.0%. The ex-dividend date of this dividend is Monday, May 4th. Sanofi’s dividend payout ratio is currently 49.16%.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.